ADAR1-dependent editing regulates human β cell transcriptome diversity during inflammation.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2022
Historique:
received: 30 09 2022
accepted: 01 11 2022
entrez: 15 12 2022
pubmed: 16 12 2022
medline: 17 12 2022
Statut: epublish

Résumé

Enterovirus infection has long been suspected as a possible trigger for type 1 diabetes. Upon infection, viral double-stranded RNA (dsRNA) is recognized by membrane and cytosolic sensors that orchestrate type I interferon signaling and the recruitment of innate immune cells to the pancreatic islets. In this context, adenosine deaminase acting on RNA 1 (ADAR1) editing plays an important role in dampening the immune response by inducing adenosine mispairing, destabilizing the RNA duplexes and thus preventing excessive immune activation. Using high-throughput RNA sequencing data from human islets and EndoC-βH1 cells exposed to IFNα or IFNγ/IL1β, we evaluated the role of ADAR1 in human pancreatic β cells and determined the impact of the type 1 diabetes pathophysiological environment on ADAR1-dependent RNA editing. We show that both IFNα and IFNγ/IL1β stimulation promote ADAR1 expression and increase the A-to-I RNA editing of Alu-Containing mRNAs in EndoC-βH1 cells as well as in primary human islets. We demonstrate that ADAR1 overexpression inhibits type I interferon response signaling, while ADAR1 silencing potentiates IFNα effects. In addition, ADAR1 overexpression triggers the generation of alternatively spliced mRNAs, highlighting a novel role for ADAR1 as a regulator of the β cell transcriptome under inflammatory conditions.

Identifiants

pubmed: 36518246
doi: 10.3389/fendo.2022.1058345
pmc: PMC9742459
doi:

Substances chimiques

Adenosine Deaminase EC 3.5.4.4
Interferon Type I 0
RNA, Double-Stranded 0
RNA, Messenger 0
RNA-Binding Proteins 0
ADAR protein, human EC 3.5.4.37

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1058345

Subventions

Organisme : NIDDK NIH HHS
ID : U01 DK127786
Pays : United States

Informations de copyright

Copyright © 2022 Szymczak, Cohen-Fultheim, Thomaidou, de Brachène, Castela, Colli, Marchetti, Levanon, Eizirik and Zaldumbide.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Nat Genet. 2012 Nov;44(11):1243-8
pubmed: 23001123
Genome Biol. 2014;15(12):550
pubmed: 25516281
J Biol Chem. 2017 Feb 24;292(8):3466-3480
pubmed: 28077579
Mol Ther. 2004 Feb;9(2):209-17
pubmed: 14759805
F1000Res. 2015 Dec 30;4:1521
pubmed: 26925227
Cell Metab. 2018 Dec 4;28(6):946-960.e6
pubmed: 30078552
Front Immunol. 2019 Jul 25;10:1763
pubmed: 31404141
Nat Commun. 2020 Feb 7;11(1):799
pubmed: 32034135
Nat Genet. 2019 Nov;51(11):1588-1595
pubmed: 31676868
Cell Death Dis. 2019 Dec 4;10(12):913
pubmed: 31801951
J Biol Chem. 2022 Sep;298(9):102267
pubmed: 35850307
EBioMedicine. 2018 Oct;36:367-375
pubmed: 30269996
Front Endocrinol (Lausanne). 2020 Sep 15;11:568446
pubmed: 33042023
Biomedicines. 2021 Feb 17;9(2):
pubmed: 33671312
F1000Res. 2015 Oct 14;4:1070
pubmed: 26674615
Front Oncol. 2020 Dec 10;10:593989
pubmed: 33363023
Trends Microbiol. 2019 Jan;27(1):75-85
pubmed: 30201512
Bioessays. 2017 Nov;39(11):
pubmed: 28960389
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
J Clin Invest. 2011 Sep;121(9):3589-97
pubmed: 21865645
Diabetologia. 2020 Oct;63(10):1999-2006
pubmed: 32894310
Nat Methods. 2019 Nov;16(11):1131-1138
pubmed: 31636457
Front Immunol. 2021 Apr 19;12:667989
pubmed: 33953728
Tumour Biol. 2017 Oct;39(10):1010428317734816
pubmed: 29022489
Microorganisms. 2020 Sep 15;8(9):
pubmed: 32942706
Cell Rep. 2018 Apr 3;23(1):50-57
pubmed: 29617672
Nat Commun. 2014 Aug 27;5:4726
pubmed: 25158696
Front Endocrinol (Lausanne). 2022 Sep 12;13:991632
pubmed: 36171907
Nat Rev Mol Cell Biol. 2016 Feb;17(2):83-96
pubmed: 26648264
Nat Rev Endocrinol. 2021 Mar;17(3):150-161
pubmed: 33293704
Nat Commun. 2020 May 22;11(1):2584
pubmed: 32444635
Mol Cell Biol. 2005 Aug;25(16):6956-63
pubmed: 16055709
Genome Res. 2014 Mar;24(3):365-76
pubmed: 24347612
J Exp Med. 1997 Feb 3;185(3):531-9
pubmed: 9053453
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Sci Adv. 2021 Jan 6;7(2):
pubmed: 33523973
J Mol Med (Berl). 2016 Oct;94(10):1095-1102
pubmed: 27044320
Nat Rev Endocrinol. 2020 Jul;16(7):349-362
pubmed: 32398822
Nat Methods. 2017 Apr;14(4):417-419
pubmed: 28263959
J Autoimmun. 2018 Nov;94:7-15
pubmed: 30115527
Cell Stem Cell. 2020 Aug 6;27(2):300-314.e11
pubmed: 32396862
J Transl Med. 2019 Sep 23;17(1):319
pubmed: 31547885

Auteurs

Florian Szymczak (F)

ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, Brussels, Belgium.

Roni Cohen-Fultheim (R)

Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat Gan, Israel.

Sofia Thomaidou (S)

Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands.

Alexandra Coomans de Brachène (AC)

ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, Brussels, Belgium.

Angela Castela (A)

ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, Brussels, Belgium.

Maikel Colli (M)

ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, Brussels, Belgium.

Piero Marchetti (P)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Erez Levanon (E)

Institute of Nanotechnology and Advanced Materials, Bar-Ilan University, Ramat Gan, Israel.

Decio Eizirik (D)

ULB Center for Diabetes Research, Medical Faculty, Université Libre de Bruxelles, Brussels, Belgium.

Arnaud Zaldumbide (A)

Department of Cell and Chemical Biology, Leiden University Medical Center, Leiden, Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH